Equities

ReNeuron Group PLC

RENE:LSE

ReNeuron Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.38
  • Today's Change0.00 / 0.00%
  • Shares traded177.62k
  • 1 Year change-59.09%
  • Beta1.1898
Data delayed at least 20 minutes, as of Feb 05 2024 14:22 GMT.
More ▼

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  • Revenue in GBP (TTM)249.00k
  • Net income in GBP-5.07m
  • Incorporated2005
  • Employees34.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 20 3819 8400Fax+44 14 8353 4864
  • Websitehttps://www.reneuron.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Ovoca Bio PLC0.00-2.00m612.97k5.00612.97k5.00
Voyager Life PLC314.00k-1.10m630.13k28.00630.13k28.00
Nuformix PLC0.00-436.95k1.43m2.001.43m2.00
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
N4 Pharma PLC1.95k-1.28m2.15m5.002.15m5.00
Hellenic Dynamics PLC-100.00bn-100.00bn2.96m25.002.96m25.00
Fusion Antibodies PLC1.58m-2.84m3.19m50.003.19m50.00
TheraCryf PLC838.00k-3.35m3.21m7.003.21m7.00
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m3.76m7.003.76m7.00
IXICO PLC6.67m-1.18m3.93m89.003.93m89.00
ValiRx Plc0.00-2.41m4.30m8.004.30m8.00
BSF Enterprise PLC12.94k-1.50m5.17m4.005.17m4.00
Data as of Feb 05 2024. Currency figures normalised to ReNeuron Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 04 Jun 20213.35m0.00%
Hargreaves Lansdown Asset Management Ltd.as of 01 Feb 20243.34m0.00%
Schroder Investment Management Ltd.as of 12 Mar 20212.84m0.00%
KW Investment Management Ltd.as of 01 Feb 20242.79m0.00%
IG Markets Ltd.as of 01 Feb 20242.38m0.00%
HSBC Bank Plc (Market-Maker)as of 01 Feb 2024698.00k0.00%
Toscafund Asset Management LLPas of 31 Dec 2022667.11k0.00%
abrdn Investments Ltd.as of 01 Feb 2024591.00k0.00%
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024583.00k0.00%
Partners Investment Co. LLPas of 11 Feb 2020531.85k0.00%
More ▼
Data from 11 Feb 2020 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.